nebivolol 10 mg
1. INDICATIONS AND USAGE Nebivolol is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension Nebivolol tablets are indicated for the treatment of hypertension, to lower blood pressure [see Clinical Studies ( 14.1 )]. Nebivolol tablets may be used alone or in combination with other antihypertensive agents [see Drug Interactions ( 7 )]. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nebivolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
Solco Healthcare US, LLC
TRIANGLE PINK S 673
S 673 TRIANGLE PINK
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16. HOW SUPPLIED/STORAGE AND HANDLING
NEBIVOLOL tablets are available for oral administration containing
NEBIVOLOL hydrochloride equivalent to 2.5, 5, 10, and 20 mg of
NEBIVOLOL.
NEBIVOLOL tablets are triangular-shaped, biconvex, unscored, differentiated by color and are debossed with “S” on one side and the number (671, 672, 673, or 674) on the other side.
NEBIVOLOL tablets are supplied in the following strengths and package configurations:
NEBIVOLOL Tablets Tablet Strength Package Configuration NDC # Tablet Color 2.5 mg Bottle of 30 with child-resistant closure 43547-524-03 Light blue Bottle of 90 with child-resistant closure 43547-524-09 Bottle of 500 with child-resistant closure 43547-524-50 5 mg Bottle of 30 with child-resistant closure 43547-525-03 Light yellow Bottle of 90 with child-resistant closure 43547-525-09 Bottle of 500 43547-525-50 10 mg Bottle of 30 with child-resistant closure 43547-526-03 pink Bottle of 90 with child-resistant closure 43547-526-09 Bottle of 500 43547-526-50 20 mg Bottle of 30 with child-resistant closure 43547-527-03 Light blue Bottle of 90 with child-resistant closure 43547-527-09 Bottle of 500 43547-527-50 Store at 20 o to 25 o C (68 o to 77 o F); excursions permitted between 15 o and 30 o C (59 o and 86 o F) [see USP for Controlled Room Temperature] . Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.
More pills like TRIANGLE S 673